Last updated: March 2026
Bronchogen (Ala-Glu-Asp-Leu) is a Khavinson bioregulator tetrapeptide designed for respiratory tissue research. With a molecular weight of 446.45 g/mol, this small peptide crosses cellular membranes to interact with bronchial tissue at the molecular level.
Bronchogen belongs to the Khavinson bioregulator family — short peptides that interact with DNA to modulate gene expression in specific tissues. Bronchogen targets bronchial and respiratory tissue, with proposed bronchodilating and anti-inflammatory properties.
Designed to interact specifically with bronchial epithelial cells and respiratory tissue. The AEDL sequence shows preferential binding to lung-tissue DNA regulatory regions.
Research suggests bronchodilating effects — relaxing airway smooth muscle to improve airflow. May modulate expression of genes controlling bronchial tone.
Anti-inflammatory properties in respiratory tissue models. May reduce inflammatory cytokine expression in bronchial cells, potentially relevant for respiratory conditions.
As a bioregulator, proposed to support cellular repair and regeneration in respiratory tissue by restoring peptide pools that decline with aging and damage.
Context: Bronchogen research is early-stage and limited. Data comes from in vitro cell models and the broader Khavinson bioregulator framework. No clinical trials in respiratory patients have been published. The evidence base is significantly thinner than for compounds like Epitalon.
Self-Assessment
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Third-party tested compounds from Swiss Chems — one of the most trusted research suppliers.
Affiliate link — supports MeetPeptide at no extra cost.
Bronchogen is NOT FDA approved and is available only for research purposes. Evidence is very limited. This page is for educational purposes only. Not medical advice. Research Only